ASCO 2019 – Lenalidomide reduces risk that smoldering myeloma will progress to myeloma in high risk patients
The phase II/III E3A06 randomized clinical trial found that lenalidomide (Revlimid) significantly reduces the risk of smoldering multiple myeloma (SMM) — a precancerous condition — from progressing to cancer in patients at moderate or…